US Patent

US11813251 — Methods of treating gastrointestinal stromal tumors

Method of Use · Assigned to Deciphera Pharmaceuticals LLC · Expires 2040-08-12 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating gastrointestinal stromal tumors by administering a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3750`	—

Patent Metadata

Patent number: US11813251
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-12
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.